Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026?

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a promising investment opportunity in the healthcare sector, with a consensus Buy rating from analysts and significant upside potential [1][2]. Analyst Ratings - All 13 analysts covering Soleno Therapeutics have assigned a 'Buy' or equivalent rating, indicating strong market confidence [1]. - Kristen Kluska from Cantor Fitzgerald maintains a 'Buy' rating with a price target of $123, while Kate Dellorusso from LifeSci Capital also holds a 'Buy' rating with a target of $110 [2]. - Wells Fargo's Derek Archila has reduced his price target to $106 from $123 but retains an 'Overweight' rating, citing the potential of Vykat XR as a significant drug for Prader-Willi syndrome [3]. - Wolfe Research initiated coverage with an 'Outperform' rating and a price target of $75, suggesting a nearly 44% upside from the current price, driven by the recent FDA approval of Vykat XR [3]. Company Overview - Soleno Therapeutics, Inc. is a California-based clinical-stage biopharmaceutical company founded in 1999, focusing on novel therapeutics for serious illnesses, specifically offering Diazoxide Choline Extended-Release tablets [4].